Reward your curiosity. Click here to watch the trailer.

Buy now! and support our work to increase global awareness of Ibogaine.

If you are interested in setting up a local screening, LunArt Productions is happy to assist. We can send a promotion package with flyers an posters and DVDs for sales at the event. Please read our policy and contact us to inform us about your plans.

Ibogaine is a substance which is derived from the root of the 'Tabernanthe Iboga', an African plant that grows in Gabon. This plant is originally used during initiations of the Bwiti culture, to get in contact with the ancestors. These initiations are conducted for healing purposes and as a ritual when a child becomes an adult. This holy plant has become the core of this Central West African culture.

After the ingestion of the grinded root of the plant, the initiated gets dreamlike visions, in which he commonly re-experiences elements of his past and in this way gains insight in his own personality. This psychoactive phase lasts about 36 hours and has its peak about 4 hours after ingestion, where after the effect slowly decreases to end in a short sleep.

In the beginning of the sixties, a young American man called Howard Lotsof discovered that after ingesting Ibogaine, he could instantly stop his heroin use without having any withdrawal symptoms or craving. Next to that he had gained more insight in the cause and nature of his addiction because of the psychoactive phase he had gone thru.

He started to investigate this discovery, despite the lack of interest of the pharmaceutical companies and the government of the US. After he started NDA International Inc. (New Drug Application) in 1986, he finally patented Ibogaine as an addiction interrupter with the name 'Endabuse'. The Ibogaine molecule on its own cannot be patented, because it's a natural substance. This is according to some people one of the reasons why the pharmaceutical companies are not interested in the development of this substance. Also the findings of a research the CIA conducted in the sixties are according to some kept strictly confidential.

Addict-care organizations don't want to have anything to do with Ibogaine, and the people who conduct treatments are often not taken seriously by the regular treatment providers. In America Ibogaine is classified as 'schedule 1', which means that it is drug without any medicinal value that is considered dangerous. It has the same schedule as LSD, heroin, cocaine and other narcotics. That's why people such as the neurologist Dr. Deborah C. Mash conducts her treatments outside the borders of the American law. Also in Belgium Ibogaine is made illegal shortly after the negotiations between the Belgian pharmaceutical company 'Omnichem', at that time the most important producer of Ibogaine, and NDA International started.

Ibogaine is surrounded by controversy and the decisions about the use of Ibogaine in the treatment of addiction appear to be made on political and economical, instead of rational basis. Despite the results that show that Ibogaine is possibly a very useful tool for the treatment of addiction that can enhance the quality of the life of many heroin and poly-drug addicts (without functioning as a maintenance drug), the pharmaceutical companies and the government show no interest and stay very sceptical. Is it because of the economic interests or because it is a psychoactive substance? Ibogaine has provided us with more insight in the mechanisms of addiction and the question if it needs to be used for treating this huge Western problem gets more and more acknowledgement.